High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This study is a multicentra, prospective study. The enrolled patients are HP positive. They are diagnosed as HP positive by rapid urease test and/or 13C urea breath test. According to the declaration of Helsinki, 200 patients will be included in this study. After obtaining the written informed consent of the patients, HP culture and drug sensitivity test will be conducted on all the selected patients with the success rate, adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Ability and willingness to participate in the study and to sign and give informed consent

• Confirmed H. pylori infection

Locations
Other Locations
China
Hebi People's Hospital
RECRUITING
Hebi
Jiaozuo People's Hospital
RECRUITING
Jiaozuo
Luoyang central Hospital
RECRUITING
Luoyang
The first people's hospital of ping ding shan
RECRUITING
Pingdingshan
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING
Shanghai
Xuchang central Hospital
RECRUITING
Xuchang
The Second Affiliated Hospital of Henan University of science and technology
RECRUITING
Zhengzhou
The Third People's Hospital of Zhengzhou
RECRUITING
Zhengzhou
Zhengzhou People's Hospital
RECRUITING
Zhengzhou
Zhoukou Central Hospital
RECRUITING
Zhoukou
Time Frame
Start Date: 2024-08-21
Estimated Completion Date: 2026-08-30
Participants
Target number of participants: 200
Treatments
Experimental: Dual therapy
Experimental: Minocycline bismush quadruple therapy
Related Therapeutic Areas
Sponsors
Leads: Shanghai Jiao Tong University School of Medicine

This content was sourced from clinicaltrials.gov

Similar Clinical Trials